Fleischmann RM, van der Heijde D, Strand V, Atsumi T, et al. Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2). Ann Rheum Dis 2023 Sep 12:ard-2023-224482. doi: 10.1136/ard-2023-224482.
PMID: 37699654